Sprint health care! Haussen amethyst tablets cut price by 50%

On August 26, Shaanxi Provincial Public Resources Trading Center issued a notice, according to the enterprise application, Jiangsu Hausen Pharmaceutical Group Co., Ltd. production of amethystine tablets (55mg x 20 tablets / box) hanging net limit price from 19600 yuan / box adjusted to 9800 yuan / box, the adjusted price will be implemented from now on.
at a critical stage in the preparations for health care negotiations, Haussen Amedini offered to cut prices by 50%, a clear show of its determination to sprint health care.
August 18, the National Health Insurance Administration announced the 2020 National Health Insurance Drug Catalog Adjustment Work Programme and the 2020 National Health Insurance Drug Catalog Adjustment Reporting Guidelines, the biggest change from the previous draft is to relax the time range for new drug access, the new drug approval deadline, from December 31, 2019 to August 17, 2020.
Hausen's Amedini (commodity name: Ameer) was approved on March 17, 2020, according to the previous draft of the consultation will not be in this health care negotiations, after the relaxation of time will be a number of new class 1 drugs into this health care negotiations, such as Zebutini capsules in Baiji Shenzhou, human medicine industry injection benzodiazepone, Silver Valley Pharmaceuticals benzodiazebenzene nasal spray.
Amele ® is the first three-generation EGFR-TKI innovative drug developed by Haussen Pharmaceuticals and approved by NMPA on March 17, 2020 for "past mesothyl growth factors" The treatment of the subject (EGFR) tyrosine kinase inhibitor (TKI), and the treatment of adult patients with local late stage or metastasis non-small cell lung cancer (NSCLC) who are positive for the T790M mutation, is also the second third generation EGFR-TKI in the world.
's previously published clinical results show that its excellent effectiveness and safety will give more patients with advanced non-small cell lung cancer (NSCLC) hope for long-term survival, if successfully negotiated into health insurance, will bring new drug options to domestic patients, while further reducing the burden of medication.
five key phase time nodes for the 2020 drug catalog adjustment are as follows: (i) preparation phase (July-August 2020) (ii) reporting phase (August-September 2020) (iii) Expert review phase (September-October 2020) (iv) negotiation and bidding Stage (October-November 2020) (V) Announcement Results Phase (November-December 2020) At present, enterprises should be in the active declaration stage, we have adjusted the scope of the health insurance catalog to organize the varieties that may participate in the health care negotiations for your reference (incomplete data or errors, please understand), if there are omissions, welcome to add! Finally, I hope that more good medicines and new drugs can successfully enter health insurance for the benefit of more patients.
.